Downloads
Abstract
Objectives: To evaluate the results of second - line treatment in stage IV non-small cell lung cancer patients who have acquired T790M mutation with Osimertinib.
Methods: A cross - sectional descriptive study was conducted in 22 patients with EGFR mutation positive stage IV non - small cell lung cancer who failed after first - and second - generation EGFR - TKIs therapy with presence of acquired T790M resistance mutation, were treated with Osimertinib at Da Nang Oncology Hospital from March 2020 to the end of November 2022 and follow up until the end of June 2023.
Results: The objective response rate of Osimertinib in second - line treatment was 72,7%, disease control rate was 85.4%, the median progression - free survival (PFS) was 10 months. The most common side effects of Osimertinib were rash (36.4%), diarrhea (31.8%), dry skin (22.7%), paronychia (18.2%), mucositis oral (13.6%). Most of side effects were mild, and no patient required a dose reduction or treatment interruption.
Conclusion: Osimertinib is highly effective and safe in the second-line treatment of stage IV non - small cell lung cancer with acquired T790M mutation.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249.
Lee CK, Davies L, Wu Y - L, Mitsudomi T, Inoue A, Rosell R, et al. Gefitinib or erlotinib vs chemotherapy for EGFR mutation - positive lung cancer: individual patient data
meta-analysis of overall survival. 2017; 109(6): djw279.
Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR - mutant lung cancer: distinct
natural history of patients with tumors harboring the T790M mutation. 2011; 17(6): 1616-1622.
Khozin S, Weinstock C, Blumenthal GM, Cheng J, He K, Zhuang L, et al. Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer. 2017; 23(9): 2131-2135.
Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, et al. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-
cell lung cancer: AURA 3 trial. 2018; 109(6): 1930-1938.
Mok TS, Wu Y - L, Ahn M - J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum - pemetrexed in EGFR T790M - positive lung cancer. 2017;376(7): 629-640.
Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R, et al. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real -world efficacy and safety in advanced/recurrent non - small cell lung carcinoma. Thorac Cancer. 2020; 11(4): 935-942.
Nguyễn Thị Bích Phượng, Đỗ Hùng Kiên. Đặc điểm lâm sàng, cận lâm sàng và kết quả bước đầu điều trị ung thư phổi không tế bào nhỏ giai đoạn muộn có đột biến gen
T790M thứ phát bằng thuốc ức chế Tirosine Kinase thế hệ 3 - Osimertinib. Tạp chí Y học Việt Nam. 2022; 519(1).
Yi L, Fan J, Qian R, Luo P, Zhang JJIjoc. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. 2019; 145(1): 284-294.
Nguyễn Thị Lựu, Phạm Cẩm Phương. Kết quả điều trị bước 2 bằng Osimertinib bệnh ung thư phổi không tế bào nhỏ có đột biến EGFR tại bệnh viện Bạch Mai. Tạp chí Y học Việt Nam. 2023; 521(2).
| Published | 26-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 91 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.91.5 | |
| Keywords | Ung thư phổi không tế bào nhỏ, đột biến EGFR T790M thứ phát, Osimertinib Non - small cell lung cancer, EGFR T790M mutation, Osimertinib |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital